Oscotec Inc. (KOSDAQ:039200)
South Korea flag South Korea · Delayed Price · Currency is KRW
31,250
+50 (0.16%)
Aug 8, 2025, 3:30 PM KST

Oscotec Company Description

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.

It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in Phase 1a/1b clinical trials for the treatment of Alzheimer’s disease.

The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide.

In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases.

The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999.

Oscotec Inc. was founded in 1998 and is headquartered in Seongnam, South Korea.

Oscotec Inc.
CountrySouth Korea
Founded1998
IndustryDrug Manufacturers - General
SectorHealthcare
Employees51
CEOJeung-Keun Kim

Contact Details

Address:
A Building, Korea Bio Park
Seongnam, 13488
South Korea
Phone82 3 1628 7613
Websiteoscotec.com

Stock Details

Ticker Symbol039200
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
ISIN NumberKR7039200001
SIC Code3842

Key Executives

NamePosition
Jeung-Keun KimChief Executive Officer